Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 30, 2010

View Archived Issues

Identification of HIV integrase inhibitor BMS-727740 described by Bristol-Myers Squibb

H1N1 vaccine Pandemrix fails to provide protection in kidney transplant recipients

PSN-632408 stimulates replication of beta-cells in preclinical study

Marina Biotech sells carbetocin assets to Cypress Bioscience

ADX-71149 completes phase I program and moves towards phase II

ADDF awards grant to AgeneBio to develop neural stabilizer technology

Kyowa Hakko Kirin to conduct KW-2246 trials for cancer pain in Japan

Tasigna approved in Switzerland for Ph+ chronic myeloid leukemia

Bioheart reports improvements in heart failure patients

Pharmagenesis identifies new triptolide compounds

European Commission updates license for Cervarix HPV vaccine

EMA investigates potential relationship between Pandemrix and narcolepsy

Otsuka Pharmaceutical Factory claims new lipoprotein lipase-activating agents

Daiichi Sankyo reports first quarter highlights of fiscal 2010

Exelixis discovers new inhibitors of ceramide glucosyltransferase

Vitae Pharmaceuticals discloses novel 11beta-HSD1 inhibitors

Astellas Pharma identifies new serotonin 5-HT5A receptor ligands

Schering presents new agonists of free fatty acid receptor 1

Abbott and Eisai submit application for new indication of Humira in JIA

Results reported from phase II trial of cariprazine in bipolar depression

Sanofi-aventis submits proposal to acquire Genzyme

Merck KGaA begins phase Ib trial of IMO-2055 in SCCHN

Asenapine exposure increased in older patients with psychotic symptoms

Risperidone may have the potential to treat alcohol dependence

Antitope and Ablynx to collaborate in developing Nanobodies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...